Goldwasser F - Search Results

1

Decreased topotecan platelet toxicity with successive topotecan treatment cycles in advanced ovarian cancer patients.

Goldwasser F, Buthaud X, Gross M, Bleuzen P, Cvitkovic E, Voinea A, Jasmin C, Romain D, Misset JL. Goldwasser F, et al. Anticancer Drugs. 1999 Mar;10(3):263-5. doi: 10.1097/00001813-199903000-00002. Anticancer Drugs. 1999. PMID: 10327030 Clinical Trial.

2

Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient.

Gornet JM, Azoulay D, Lévi F, Yovine A, Misset JL, Goldwasser F. Gornet JM, et al. Among authors: goldwasser f. Anticancer Drugs. 2000 Apr;11(4):263-8. doi: 10.1097/00001813-200004000-00006. Anticancer Drugs. 2000. PMID: 10898541

3

Dose escalation of CPT-11 in combination with oxaliplatin using an every two weeks schedule: a phase I study in advanced gastrointestinal cancer patients.

Goldwasser F, Gross-Goupil M, Tigaud JM, Di Palma M, Marceau-Suissa J, Wasserman E, Yovine A, Misset JL, Cvitkovic E. Goldwasser F, et al. Ann Oncol. 2000 Nov;11(11):1463-70. doi: 10.1023/a:1026535824044. Ann Oncol. 2000. PMID: 11142487 Free article. Clinical Trial.

4

[Clinical use of oxaliplatin in solid tumors].

Goldwasser F, Misset JL. Goldwasser F, et al. Bull Cancer. 2001 Aug;88 Spec No:S40-4. Bull Cancer. 2001. PMID: 11567913 Free article. Review. French.

5

Topotecan preceded by oxaliplatin using a 3 week schedule: a phase I study in advanced cancer patients.

Gross-Goupil M, Lokiec F, Lopez G, Tigaud JM, Hasbini A, Romain D, Misset JL, Goldwasser F. Gross-Goupil M, et al. Among authors: goldwasser f. Eur J Cancer. 2002 Sep;38(14):1888-98. doi: 10.1016/s0959-8049(02)00232-0. Eur J Cancer. 2002. PMID: 12204671 Clinical Trial.

6

Paclitaxel (Taxol)-associated junctional tachycardia.

Faivre S, Goldwasser F, Soulié P, Misset JL. Faivre S, et al. Among authors: goldwasser f. Anticancer Drugs. 1997 Aug;8(7):714-6. doi: 10.1097/00001813-199708000-00011. Anticancer Drugs. 1997. PMID: 9311449

7

Cellular pharmacology of the combination of oxaliplatin with topotecan in the IGROV-1 human ovarian cancer cell line.

Goldwasser F, Bozec L, Zeghari-Squalli N, Misset JL. Goldwasser F, et al. Anticancer Drugs. 1999 Feb;10(2):195-201. doi: 10.1097/00001813-199902000-00008. Anticancer Drugs. 1999. PMID: 10211550

8

Severe hemolytic uremic syndrome in an advanced ovarian cancer patient treated with carboplatin and gemcitabine.

Gross M, Hiesse C, Kriaa F, Goldwasser F. Gross M, et al. Among authors: goldwasser f. Anticancer Drugs. 1999 Jul;10(6):533-6. doi: 10.1097/00001813-199907000-00004. Anticancer Drugs. 1999. PMID: 10885900

9

Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.

Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Zeghari-Squalli N, et al. Among authors: goldwasser f. Clin Cancer Res. 1999 May;5(5):1189-96. Clin Cancer Res. 1999. PMID: 10353756

10

Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics.

Wasserman E, Cuvier C, Lokiec F, Goldwasser F, Kalla S, Méry-Mignard D, Ouldkaci M, Besmaine A, Dupont-André G, Mahjoubi M, Marty M, Misset JL, Cvitkovic E. Wasserman E, et al. Among authors: goldwasser f. J Clin Oncol. 1999 Jun;17(6):1751-9. doi: 10.1200/JCO.1999.17.6.1751. J Clin Oncol. 1999. PMID: 10561212 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

340 results

Search Page

Filters